Evidence map›Paper›PMID 42620434›Full record

ArticleFrontiers in pediatrics2026

Exploratory clinical and urodynamic changes associated with mirabegron-containing multimodal treatment in children with non-monosymptomatic nocturnal enuresis: a retrospective real-world study.

Zhenxian Cai, Jiangcun Silang, Xue Ma, Dunzhu Gesang

Abstract read
In one paragraph

Article in Frontiers in pediatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Zhenxian Cai *Department of Urology, The First Affiliated Hospital of Xizang University (The Second People's Hospital of Xizang Autonomous Region), Lhasa, China.
Jiangcun Silang *Department of Urology, People's Hospital of Xizang Autonomous Region, Lhasa, China.
Xue MaDepartment of Urology, West China Hospital of Sichuan University, Chengdu, China.
Dunzhu GesangDepartment of Neurosurgery, The First Affiliated Hospital of Xizang University (The Second People's Hospital of Xizang Autonomous Region), Lhasa, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Evidence regarding mirabegron-containing treatment for children with non-monosymptomatic nocturnal enuresis (NMNE) is limited, and its independent effects require controlled evaluation. Objective: To describe exploratory clinical and urodynamic changes observed after mirabegron-containing multimodal treatment in children with NMNE. Methods: We retrospectively reviewed 31 children with NMNE who received mirabegron-containing treatment at the outpatient clinic of West China Hospital of Sichuan University between July 2024 and March 2025. Mirabegron was added to first-line treatment when voiding diaries suggested reduced functional bladder capacity. Patients received 25 or 50 mg once nightly according to age and weight for 12 weeks, without dose adjustment. Voiding diary parameters and available urodynamic measurements were compared before and after treatment. Results: After 12 weeks, voiding frequency, daytime incontinence episodes, and nocturnal enuresis episodes decreased, while maximum voided volume increased. Maximum cystometric capacity was measured before and after treatment in all 31 patients and showed a modest within-cohort increase. Follow-up measurements of detrusor pressure at the end of filling and bladder compliance were available for only four patients. These descriptive data showed lower detrusor pressure and higher bladder compliance after treatment. Based on nocturnal enuresis episode reduction, 28 of 31 patients (90.3%) met the predefined diary-based improvement threshold. This proportion cannot be interpreted as a pharmacologic response attributable to mirabegron because treatment was multimodal and uncontrolled. No treatment-related adverse events were documented, but retrospective records are insufficient to establish safety. Conclusion: Mirabegron-containing multimodal treatment was associated with within-cohort changes in voiding diary parameters and a modest increase in maximum cystometric capacity. The retrospective, single-arm design precludes causal or treatment-specific inference, and patient-centered outcomes were not assessed. These findings are preliminary, exploratory, and hypothesis-generating rather than practice-informing.

Indexed as

bladder compliancechildrenlower urinary tract symptomsmirabegronnon-monosymptomatic nocturnal enuresisoveractive bladderpediatric urologyurodynamics

Identifiers

PMID42620434
PMCPMC13485917

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.